Skip to content
Free standard shipping over $250 · Dispatched from Australian stock

SLU-PP-332 dosage in studies: doses, timing and reconstitution

None of the SLU-PP-332 abstracts in these records states a dose, a route or a treatment length. The two in-vivo studies were in mice, and they describe the compound as 'administered' without giving amounts. Nothing here is a dosing recommendation, and no human dose has been studied.

There is no established SLU-PP-332 dose in the research record, because the compound has never been studied in people. The only living-animal work in these records is in mice, and neither abstract states how much was given, by what route or how often.

Billon et al. (2024) gave SLU-PP-332 to diet-induced obese and ob/ob mice and measured energy expenditure, fatty acid oxidation, fat mass and insulin sensitivity. Xu et al. (2024) tested it in a pressure-overload heart failure model, with metabolomics taken at 6 weeks. The Circulation paper notes that ERR agonists with pharmacokinetics suitable for in-vivo use had not previously been available, which is part of why SLU-PP-332 was designed.

The other records work at the cell or enzyme level: a structure-activity study in cell assays and two metabolite studies in human liver fractions. Concentrations used in those assays are not given in the abstracts, and they would not translate to a dose in an animal or a person in any case.

A mouse dose cannot be carried across to humans by simple arithmetic, and no human study exists to check it against. Tasman does not publish dosing guidance for SLU-PP-332. The table on this page records only what each study reported, which for this compound is mostly that the amount was not stated.

Doses used by each cited study

StudyModelDoseFrequencyDuration
Billon C et al. 2024Mouse, diet-induced obese and ob/obNot stated in the abstractNot stated in the abstractNot stated in the abstract
Xu W et al. 2024Mouse, pressure overload-induced heart failureNot stated in the abstractNot stated in the abstract6-week pressure overload; treatment length not stated in the abstract

This table reports what each study used. It is not a recommendation or an instruction.

Vial maths

VialBAC waterConcentrationPer 0.01 mL (1 unit, U-100)
5 mg1 mL5 mg/mL50 mcg
5 mg2 mL2.5 mg/mL25 mcg
5 mg3 mL1.667 mg/mL16.7 mcg

Open the calculator (pre-set for SLU-PP-332)